Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suvorexant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 known ✓ | O43614 | 20/20 | 1.00 |
| ▸ | HCRTR1 known ✓ | O43613 | 15/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suvorexant SCHEMBL1820881 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL29357712 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL13731245 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL1586289 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL29596480 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL13372948 | 0.92 | HCRTR2 (0.85) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1818107 | 0.91 | HCRTR2 (0.84) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1653764 | 0.91 | HCRTR2 (0.84) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL12378863 | 0.91 | HCRTR2 (0.83) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1651046 | 0.90 | HCRTR2 (0.82) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| US-20210179578-A1 | OX1 ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-06-17 | — | — | US | disclosed |
| EP-3710435-A1 | OX1 ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2020-09-23 | — | — | EP | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | REDDY S LAB LIMTED DR (IN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | REDDY S LAB LIMTED DR (IN) | 2016-06-16 | — | — | US | disclosed |
| WO-2016020404-A1 | PROCESS FOR THE RESOLUTION OF (R,S)-DIAZEPANE AND DIAZEPANONE DERIVATIVES | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020403-A1 | PREPARATION OF A BENZOIC ACID DERIVATIVE AND ITS USE FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020405-A1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 5/4885NR1I2 1737/4885 |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885NR1I2 346/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885NR1I2 346/4885 |
| US-20210179578-A1 | OX1 ANTAGONISTS | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885NR1I2 230/4885 |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | HCRTR2 5/4885HCRTR1 4/4885NR1I2 228/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885NR1I2 182/4885 |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | KMO, HCRTR2, COMT | HCRTR2 2/4885HCRTR1 5/4885NR1I2 876/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 15/4885NR1I2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.